Related Experiment Videos
Gastrografin in acute meconium ileus equivalent
Archives of Disease in Childhood
|November 1, 1986
Summary
Oral Gastrografin effectively treats acute meconium ileus equivalent in cystic fibrosis patients. This outpatient treatment offers an 81% success rate and is preferred by patients over other options.
Area of Science:
- Gastroenterology
- Pediatric Pulmonology
- Radiology
Background:
- Acute meconium ileus equivalent (MIE) is a common complication in cystic fibrosis (CF) patients.
- Previous treatments for MIE have varying success rates and often require hospitalization.
Purpose of the Study:
- To evaluate the efficacy and patient preference of single-dose oral Gastrografin for treating MIE in CF patients.
- To assess the feasibility of outpatient management for MIE episodes.
Main Methods:
- A retrospective review of CF patients experiencing MIE was conducted.
- Episodes were treated with a single oral dose of Gastrografin.
- Treatment success, outpatient management rates, and patient-reported preferences were recorded.
Main Results:
- Twenty-five (37%) CF patients experienced MIE.
- 37 of 40 MIE episodes (92.5%) were treated with oral Gastrografin.
- An 81% success rate was achieved with Gastrografin treatment.
- 75% of treated episodes were managed as outpatients.
- Patients reported a preference for Gastrografin over other treatments.
Conclusions:
- Single-dose oral Gastrografin is a highly effective and well-tolerated treatment for MIE in CF patients.
- Outpatient management of MIE is feasible and successful with Gastrografin.
- Gastrografin offers a patient-preferred alternative for MIE management.